*LIBTAYO was FDA approved in advanced CSCC in September 2018.1,4
66%
of patients received LIBTAYO
as
first-line systemic therapy3
90%
of patients had received
prior
cancer-related surgery1
68%
of patients had received
prior radiotherapy1
23%
of patients with mCSCC
had only
nodal metastases1
77%
of patients with mCSCC
had
distant metastases1
CSCC=cutaneous squamous cell carcinoma; ECOG=Eastern Cooperative Oncology Group; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; PD-L1=programmed death ligand 1; PS=performance status.
Chapter 1 | Dr Whitman's and Dr Cohen's introductions |
Chapter 2 | Situations where surgery may not be appropriate for patients with locally advanced CSCC |
Chapter 3 | Situations Where radiation may not be appropriate for patients with locally advanced CSCC |
Chapter 4 | Multidisciplinary approach to assessing treatment options for locally advanced CSCC |
Chapter 5 | Overview of LIBTAYO |
Chapter 6 | Patient case study (70-year-old male with locally advanced CSCC) |
Chapter 7 | Important Safety Information |
Chapter 8 | References |
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02760498. Updated January 26, 2021. Accessed March 24, 2021. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months. Poster presented at: European Association of Dermato Oncology Congress 2021 Virtual Scientific Meeting. 15-17 April 2021. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097. Updated June 25, 2020. Accessed January 19, 2021. 5. Data on file. Regeneron Pharmaceuticals, Inc. 6. Alam M, Armstrong A, Baum C, et al; Work Group, Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578.